- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04755634
Shafer Width and Girth: The Use of Injectable Fillers for Penile Enhancement
August 18, 2022 updated by: Shafer Clinic Fifth Avenue
Injectable filler will be performed by Principal Investigator under sterile conditions for the enhancement of girth and surface area of the penis.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Director Clinical Studies
- Phone Number: 12012802127
- Email: mussarrathussain@gmail.com
Study Locations
-
-
New York
-
New York, New York, United States, 10017
- Recruiting
- Shafer Clinic Fifth Avenue
-
Contact:
- Mussarrat Hussain
- Phone Number: 212-888-7770
- Email: mussarrathussain@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males,
- 21 to 65 years of age,
- Seeking enhancement of their penile width and girth.
Exclusion Criteria:
- Patient with a history of psychological or psychiatric illness,
- Congenital or acquired penile malformation,
- Previous plastic surgery or non-invasive treatments of their penis,
- Any chronic disease such as vascular disorder, urological disorder, myocardial infarction, hypertension, cerebrovascular accident or coagulopathy.
- Patients with a history of allergic reactions to hyaluronic acid derivatives
- Individuals with penises measured less than 6 cm in length in the flaccid position
- Individuals with penises greater than 12.5 cm in length in the flaccid position.
- Individuals with uncircumcised penises
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
This is a prospective, single-arm, single-center study
|
Injectable
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase in penile width and girth
Time Frame: 1 year
|
Three-dimensional (3D) surface images taken by a digital stereophotogrammetry system at the baseline will be compared to the images taken at 1 year post-treatment follow up.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of increase in penile width and girth
Time Frame: 1 year
|
For how long duration the treatment will produce a measurable difference in penile size.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Shafer, MD, Shafer Clinic Fifth Avenue
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 23, 2021
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
February 10, 2021
First Submitted That Met QC Criteria
February 12, 2021
First Posted (Actual)
February 16, 2021
Study Record Updates
Last Update Posted (Actual)
August 22, 2022
Last Update Submitted That Met QC Criteria
August 18, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00034295
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Micropenis
-
Carmel Medical CenterWithdrawn
Clinical Trials on Hyaluronic Acid
-
Ayhman Al AfifNova Scotia Health AuthorityCompletedHead and Neck Neoplasms | Laryngeal Cancer | Head and Neck Squamous Cell Carcinoma | Voice Disorders
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Disease | Atrophic VaginitisBrazil
-
Taipei Medical UniversityShin Kong Wu Ho-Su Memorial HospitalUnknown
-
Bioventus LLCTerminatedKnee OsteoarthritisFrance, Monaco
-
Medical University of ViennaRecruiting
-
Tedec-Meiji Farma, S.A.CompletedOsteoarthritis of the KneeSpain
-
Federico II UniversityRecruiting
-
Hawler Medical UniversityCompleted
-
Istanbul UniversityCompletedKnee OsteoarthritisTurkey
-
KLSMC Stem Cells, Inc.CompletedArticular Cartilage Disorder of Knee | Articular Cartilage; DegenerationUnited States, Malaysia